Safety and immunogenicity, after nasal application of HIV-1 DNA gagp37 plasmid vaccine in young mice

Vaccine

Volumn 26, Issue 40, 2008, Pages 5101-5106

  Hinkula, Jorma ^a,b   Hagbom, Marie ^a   Wahren, Britta ^b   Schroder, Ulf ^c  

^a LINKÖPING UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Eurocine AB   (Sweden)

Author keywords

DNA plasmid; HIV 1 gag; Intranasal; N3 adjuvant; Olfactory bulb; Safety

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HUMORAL IMMUNITY; IMMUNOGENICITY; INFLAMMATION; MOUSE; NONHUMAN; NOSE MUCOSA; OLFACTORY EPITHELIUM; PRIORITY JOURNAL; TISSUE INJURY;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; AIDS VACCINES; AMINES; ANIMALS; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GLYCERIDES; HIV INFECTIONS; HIV-1; HUMANS; MICE; MICE, INBRED C57BL; NASAL MUCOSA; OLFACTORY BULB; PLASMIDS; VACCINES, DNA;

EID: 50849095773     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.03.098     Document Type: Article

References (28)

1. Mutsch M., Zhou W., Rhodes P., Bopp M., Chen R.T., Linder T., et al. Use of inactivated intranasal influenza vaccine and the risk of Bell's plasy in Switzerland. N Engl J Med 350 (2004) 896-903
2. Couch R.B. Nasal vaccination. Escherichia coli enterotoxin, and Bells palsy. N Engl J Med 350 (2004) 860-861
3. Van Ginkel F.W., Jackson R.J., Yuki Y., and McGhee J.R. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol 165 (2000) 4778-4782
4. Belyakov I.M., Derby M.A., Ahlers J.D., Kelsall B.L., Earl B.L., Moss B., et al. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-1 vaccinia challenge. Proc Natl Acad Sci USA 95 (1998) 1709-1714
5. Neutra M.R., and Kozlowski P.A. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 6 (2006) 148-158
6. Pope M.A., and Haase A.T. Transmission acute HIV-1 infection and the quest for strategies to prevent infection. Nat Med 9 (2003) 847-852
7. Baba T.W., Liska V., Hofmann-Lehman R., Vlasak J., Xu W., Ayehunie S., et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 6 (2000) 200-206
8. Devito C., Hinkula J., Kaul R., Kimani J., Kiama P., Lopalco L., et al. Cross-clade HIV-1 specific neutralizing IgA in mucosal and systemic compartments of HIV-1 exposed, persistently seronegative subjects. J AIDS 30 (2002) 413-420
9. Lizeng O., Nilsson C., Sourial S., Andersson S., Larsen O., Aaby P., et al. Potent neutralizing serum immunoglobulin A (IgA) in human immunodeficiency virus type 2 exposed IgG seronegative individuals. J Virol 78 (2004) 7016-7022
10. Ljungberg K., Rollman E., Eriksson L., Hinkula J., and Wahren B. Enhanced immune responses after DNA vaccination with combined envelope genes from different HIV-1 subtypes. Virology 302 (2002) 44-57
11. Rollman E., Hinkula J., Arteaga J., Zuber B., Kjerrstrom A., Liu M., et al. Multi-subtype gp160 DNA immunization induces broadly neutralizing anti-HIV antibodies. Gene Ther 11 (2004) 1146-1154
12. Hinkula J., Rollman E., Lundholm P., Benthin R., Okuda K., and Wahren B. Genetic immunization with multiple HIV genes provides protection against HIV-1/MuLV pseudovirus challenge in vivo. Cells Tissues Organs 177 (2004) 169-184
13. Hamajima K., Sasaki S., Fukushima J., Kaneko T., Xin K.Q., Kudho I., et al. Intranasal administration of HIV-DNA vaccine formulated with a polymer carboxymethylcellulose, augments mucosal antibody production and cell-mediated immune response. Clin Immunol Immunopathol 88 (1998) 205-210
14. Jounai N., Okuda K., Kojima V., Hamajima K., Ohba K., Klinman D., et al. Contribution of the rev gene to the immunogenicity of DNA vaccines targeting the envelope glycoprotein of HIV. J Gene Med 5 (2003) 609-617
15. Sasaki S., Hamajima K., Fukushima J., Ihata A., Ishii N., Gorai I., et al. Comparison of intranasal and intramuscular immunization against HIV-1 with a DNA-monophosphoribosyl lipid A adjuvant vaccine. Infect Immun 66 (1998) 823-826
16. Singh M., Vajdy M., Gardner J., Briones M., and O'Hagan D. Mucosal immunization with HIV-1 gag DNA on cationic microparticles prolongs gene expression and enhances local and systemic immunity. Vaccine 20 (2001) 594-602
17. Hinkula J., Svanholm C., Schwartz S., Lundholm P., Brytting M., Engstrom G., et al. Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes. J Virol 71 (1997) 5528-5539
18. Asakura Y., Lundholm P., Kjerrstrom, Benthin R., Lucht E., Fukushima J., et al. DNA-plasmids of HIV-1 induce systemic and mucosal immune responses. Biol Chem 380 (1999) 375-379
19. Rollman E., Bråve A., Boberg A., Gudmundsdotter L., Engstrom G., Isaguliants M., et al. The rationale behind a vaccine based on multiple HIV antigens. Microbes Inf 7 (2005) 1414-1423
20. Schröder U., and Svenson S.B. Nasal and parenteral immunizations with diphtheria toxic using monoglyceride/fatty Ac-id lipid suspensions as adjutants. Vaccine 17 (1999) 2096-2100
21. VanCott T.C., Kaminski R.W., Mascola J.R., Kalyanaraman V.S., Wassef N.M., Alving C.R., et al. HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160. J Immunol 160 (1998) 2000-2010
22. Devito C., Zuber B., Schroder U., Benthin R., Okuda K., Broliden K., et al. Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity. J Immunol 173 (2004) 7078-7089
23. Hinkula J., Devito C., Zuber B., Benthin R., Ferreira D., Wahren B., et al. A novel DNA adjuvant, N3, enhances mucosal and systemic immune responses induced by HIV-1 DNA and peptide immunizations. Vaccine 24 (2006) 4494-4497
24. Rollman E., Ramqvist T., Zuber B., Tegerstedt K., Kjerrstrom-Zuber A., Klingstrom J., et al. Genetic immunization is augmented by murine polyomavirua VP1 pseudocapsid. Vaccine 21 (2003) 2263-2267
25. Bråve A., Ljungberg K., Rollman E., Hinkula J., Boberg A., and Wahren B. Multi-gene/multi-subtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery. Mol Ther 12 (2005) 1197-1205
26. Bråve A., Ljungberg A., Boberg A., Rollman E., Engstrom G., Hinkula J., et al. Reduced cellular immune responses following immunization with a multi-gene HIV-1 vaccine. Vaccine 24 (2006) 4524-4526
27. Rinaldo C., Huang X.L., Faz Z.F., Ding M., Beltz L., Logar A., et al. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associates with lack of disease in HIV-1-infected long-term non-progressors. J Virol 69 (1995) 5838-5842
28. Harrer T., Harrer E., Kalams S.A., Elbeik T., Staprans S.I., Feinberg M.B., et al. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. AIDS Res Hum Retrovirus 12 (1996) 585-592